Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pacific Edge Limited ( (PFGTF) ) just unveiled an announcement.
Pacific Edge Limited announced that the US District Court for the Middle District of Pennsylvania lacks jurisdiction to review a Local Coverage Determination (LCD) related to genetic testing in oncology. This decision prevents the court from considering Pacific Edge’s legal complaint, leaving the company to rely on policy action by the Center of Medicare and Medicaid Services (CMS) to delay or retire the LCD. The outcome of this situation could significantly impact Pacific Edge’s operations and market positioning in the US, as the company awaits further actions from CMS.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. Headquartered in Dunedin, New Zealand, the company offers its Cxbladder tests globally through its laboratories in New Zealand and the USA. Cxbladder is a urine-based genomic biomarker test used for the detection and surveillance of bladder cancer, trusted by over 4,400 US urologists and accessible to a large portion of the population in New Zealand.
YTD Price Performance: 12.86%
Average Trading Volume: 16,566
Technical Sentiment Signal: Sell
Current Market Cap: $58.22M
See more insights into PFGTF stock on TipRanks’ Stock Analysis page.